Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2015 Jan 26;4(4):e996470. doi: 10.1080/2162402X.2014.996470

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2015 The Author(s). Published with license by Taylor & Francis Group, LLC

© Zhe (Jenny) Zhang, Peggy A Bulur, Ahmet Dogan, Dennis A Gastineau, Allan B Dietz, and Yi Lin

This is an Open Access article distributed under the terms of the Creative Commons Attribution-Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The moral rights of the named author(s) have been asserted.

PMC Copyright notice

Figure 2. — CD14⁺HLA-DR^low/neg monocytes promote lymphoma cell survival from chemotherapy. (A) Compared to LYM cultured alone with doxorubicin (DOX), co-culture with monocytes increased the viability of LYM cells. Quantitative analysis of live LYM cells for designated conditions are shown for Granta-519 (n = 10) and OCI-Ly10 (n = 6; mean ± SD). Representative dot plots are shown above each condition for Granta-519. (B) Co-culturing with CD14⁺HLA-DR^low/neg monocytes in the presence of DOX increased the number of live LYM cells compared to LYM alone. Quantitative analysis of number of live LYM cells under designated culture conditions are shown for 5 LYM cell lines (mean ± SD, n under each cell lines). OCI-Ly10, which did not induce decreased HLA-DR expression on monocytes, did not have increased survival from DOX. *p < 0.05.